{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:30:08Z","timestamp":1792459808078,"version":"4.5.0"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,3,7]],"date-time":"2015-03-07T00:00:00Z","timestamp":1425686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Many patients with non\u2010Hodgkin (<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>) or Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>) relapse or are refractory to initial therapy and require additional options. Bendamustine (B), lenalidomide (L) and rituximab (R) each have activity in this setting. This study was performed to determine the safety of <jats:styled-content style=\"fixed-case\">BLR<\/jats:styled-content> and its optimal phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> dose. Patients with <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> failing standard therapies received B (90\u00a0mg\/m<jats:sup>2<\/jats:sup>\u00a0days 1, 2 every 28\u00a0days), and L (escalating from 5\u00a0mg 21\/28\u00a0days) for six cycles, followed by 6\u00a0months of L. At the highest dose R 375\u00a0mg\/m<jats:sup>2<\/jats:sup> on day one of each cycle was added for patients with B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>. Histologies included diffuse large B\u2010cell lymphoma (<jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content>, 11), marginal zone lymphoma (3), <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> (2), and one each of transformed follicular lymphoma, S\u00e9zary syndrome, Waldenstr\u00f6m macroglobulinaemia and mantle cell lymphoma. Neutropenia was the most common grade 3 and 4 toxicity, but no maximum tolerated dose was identified. Of 20 patients, seven responded (35%), including four complete remissions, with five unmaintained responses from 28+ to 37+\u00a0months, including 2 <jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content>. <jats:styled-content style=\"fixed-case\">BR<\/jats:styled-content> with 20\u00a0mg l at, 21\/28\u00a0days achieved durable responses; however, in light of its modest activity, and the availability of newer targeted therapies, the future of <jats:styled-content style=\"fixed-case\">BLR<\/jats:styled-content> is uncertain.<\/jats:p>","DOI":"10.1111\/bjh.13321","type":"journal-article","created":{"date-parts":[[2015,3,7]],"date-time":"2015-03-07T07:45:34Z","timestamp":1425714334000},"page":"528-533","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas"],"prefix":"10.1111","volume":"169","author":[{"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[{"name":"Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Crawford","sequence":"additional","affiliation":[{"name":"Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,3,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.7252"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.0866"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.1844"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-314708"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2835"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1751-z"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1182\/blood.V118.21.2700.2700","article-title":"Lenalidomide, bendamustine, and rituximab as first\u2010line therapy for patients >65\u00a0years with mantle cell lymphoma: results from the phase I portion of the Nordic Lymphoma Group MCL4 (LENA\u2010BERIT) trial","volume":"118","author":"Jerkeman M.","year":"2011","journal-title":"Blood"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24714"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.820289"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.5203"},{"key":"e_1_2_6_14_1","first-page":"1013","article-title":"IMET 3393, (\u2010[1\u2010Methyl\u20105\u2010bis\u2010(\u03b2\u2010chlor\u00e4thyl)\u2010aminobenzimidazolyl\u2010(2)]\u2010butter s\u00e4urehydrochlorid, ein neues Zytostatikum aus der Reihi der Benzimidazol\u2010Loste","volume":"110","author":"Ozegowski W.","year":"1971","journal-title":"Zbl Pharm"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12361"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf189"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4405"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21468"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13321","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:35:31Z","timestamp":1696300531000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,7]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1111\/bjh.13321"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13321","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,7]]},"assertion":[{"value":"2014-09-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-01-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}